IGF-1 LR3

A Regulatory System, Deliberately Evaded

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

IGF-1 LR3's defining feature is reduced affinity for the binding proteins that normally sequester circulating IGF-1. Those proteins are a regulatory system, not an obstacle, and the compound exists to bypass them. That sits in tension with what the Laron literature reports.

Key facts

What LR3 removes
IGF binding protein affinity
What that system does
Restrains free IGF-1 availability
Laron finding
Congenital deficiency, cancer not observed
IGF-1R oncology
Pursued on that rationale
LR3 clinical development
None (a cell culture reagent)
WADA
Prohibited at all times, class S2

What the binding protein system is for

Six binding proteins hold the overwhelming majority of circulating IGF-1, largely in a ternary complex with IGFBP-3 and the acid-labile subunit. Bound IGF-1 cannot engage its receptor. The system functions simultaneously as a reservoir and a brake, keeping a large circulating pool while holding the active free fraction small and regulated.

Why a growth factor needs a brake

IGF-1 receptors are present on nearly every tissue, and the signal promotes proliferation and opposes cell death. A signal with that reach and that effect requires tight control, and the binding protein system is that control. It is not an inefficiency in the design that an engineer could improve upon.

Research material referenced

IGF-1 LR3 1mg, third-party HPLC tested

Buy IGF-1 LR3 · £49.99

What LR3 does to it

Arginine at position 3 and a thirteen-residue N-terminal extension both reduce binding protein affinity. The result is a substantially larger free fraction at the same total concentration. That is the entire purpose of the molecule, and in its intended setting (a culture dish, where secreted binding proteins are an experimental nuisance) it is a sensible design.

The tension in the data

The Laron literature reports that congenital IGF-1 deficiency is associated with absence of cancer, and IGF-1R was pursued as an oncology target on exactly that reasoning. A compound engineered to maximise free IGF-1 availability sits in obvious tension with those findings. Setting them beside each other is the honest thing to do, and this site sells the compound.

What this does and does not establish

It does not establish that IGF-1 LR3 causes cancer. No such finding exists, no clinical programme has examined it, and asserting it would be a claim without evidence. What it establishes is that the compound bypasses a regulatory system whose biology is well documented, and that the documentation points in a direction worth knowing about.

Why the compound stayed in a dish

This is a reasonable part of the explanation for why LR3 was never taken into clinical development. Bypassing IGFBP regulation is desirable in vitro, where it is a nuisance variable, and is a different proposition in an organism where the same system regulates a growth factor acting on every tissue. It remains investigational nowhere, unlicensed everywhere, and prohibited in sport under WADA class S2 at all times.

Frequently asked questions

What does IGF-1 LR3 change?

It reduces affinity for the IGF binding proteins, raising the free fraction available to engage receptors at a given total concentration.

Does that mean it causes cancer?

No such finding exists and no clinical programme has examined it. What can be said is that it bypasses a regulatory system whose biology is well documented.

Why was it never developed clinically?

Bypassing IGFBP regulation is useful in a culture dish where it is a nuisance. In an organism the same system regulates a growth factor acting on every tissue.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More IGF-1 LR3 articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.